The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 22, 2011
Filed:
Apr. 04, 2008
Stefanie Keil, Franfurt am Main, DE;
Karl Schoenafinger, Alzenau, DE;
Hans Matter, Frankfurt am Main, DE;
Matthias Urmann, Frankfurt am Main, DE;
Maike Glien, Frankfurt am Main, DE;
Wolfgang Wendler, Frankfurt am Main, DE;
Hans-ludwig Schaefer, Frankfurt am Main, DE;
Eugen Falk, Frankfurt am Main, DE;
Stefanie Keil, Franfurt am Main, DE;
Karl Schoenafinger, Alzenau, DE;
Hans Matter, Frankfurt am Main, DE;
Matthias Urmann, Frankfurt am Main, DE;
Maike Glien, Frankfurt am Main, DE;
Wolfgang Wendler, Frankfurt am Main, DE;
Hans-Ludwig Schaefer, Frankfurt am Main, DE;
Eugen Falk, Frankfurt am Main, DE;
Sanofi-Aventis, Paris, FR;
Abstract
The present invention comprises 4-Oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, the derivatives thereof and salts thereof as well as processes for their preparation and methods for their use as pharmaceutical compositions. More specifically, the invention relates to 4-oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives that exhibit peroxisome proliferator activator receptor (PPAR) PPARalpha, PPARdelta and PPARgamma agonist activity. The compounds themselves are defined by the structure of the formula I, wherein the various unnamed substituents are defined herein. The compounds are suitable for the treatment of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.